Long Shortz with Orthocell: Remplir adoption rises as global expansion builds

Host Tylah Tully chats with Orthocell (ASX:OCC) managing director and CEO Paul Anderson about the growing momentum behind Remplir, as surgeons find  a new indication for the company’s lead product.

Most recently, the device has been adopted in prostate surgery, with more than 100 patients treated to date.

Anderson outlines the company’s expanding global footprint following approvals of Remplir in Singapore, Hong Kong, Thailand and Canada, while maintaining a core focus on scaling in the US market.

He also highlights Orthocell’s strengthened balance sheet after a $30 million placement, positioning the company to accelerate US commercialisation and expand manufacturing capacity.

Watch the video to hear what’s on the cards for 2026.

This video was developed in collaboration with Orthocell, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.